CR20190331A - UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) - Google Patents

UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)

Info

Publication number: CR20190331A
Authority: CR; Costa Rica
Prior art keywords: del; androgénico; androgen receptor; receptor; modulador
Prior art date: 2012-06-07

Application number

CR20190331A

Other languages

English (en)

Inventor

Nicholas D Smith

Mark R Herbert

Ouathek Ouerfelli

Anna Dilhas

Original Assignee

Aragon Pharmaceuticals Inc

Sloan Kettering Inst Cancer Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-07

Filing date

2013-06-04

Publication date

2019-11-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-04 Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer Res filed Critical Aragon Pharmaceuticals Inc

2019-11-12 Publication of CR20190331A publication Critical patent/CR20190331A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

CR20190331A 2012-06-07 2013-06-04 UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) CR20190331A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261656888P	2012-06-07	2012-06-07
PCT/US2013/044116 WO2013184681A1 (en)	2012-06-07	2013-06-04	Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number	Publication Date
CR20190331A true CR20190331A (es)	2019-11-12

Family

ID=49712550

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CR20190331A CR20190331A (es)	2012-06-07	2013-06-04	UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
CR20140549A CR20140549A (es)	2012-06-07	2014-12-01	Formas cristalinas de un modulador del receptor androgénico

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CR20140549A CR20140549A (es)	2012-06-07	2014-12-01	Formas cristalinas de un modulador del receptor androgénico

Country Status (45)

Country	Link
US (9)	US9481663B2 (es)
EP (4)	EP3922629A1 (es)
JP (3)	JP6182209B2 (es)
KR (2)	KR102195916B1 (es)
CN (3)	CN105693692A (es)
AU (3)	AU2013271751B2 (es)
BR (1)	BR112014030678A2 (es)
CA (4)	CA3008345C (es)
CL (1)	CL2014003331A1 (es)
CO (1)	CO7240407A2 (es)
CR (2)	CR20190331A (es)
CY (4)	CY1120393T1 (es)
DK (3)	DK3348553T3 (es)
EA (3)	EA201992010A1 (es)
EC (1)	ECSP14030098A (es)
ES (3)	ES2809738T3 (es)
FR (1)	FR21C1050I2 (es)
GT (1)	GT201400283A (es)
HK (2)	HK1210175A1 (es)
HR (3)	HRP20180902T1 (es)
HU (4)	HUE054595T2 (es)
IL (5)	IL267608B2 (es)
IN (1)	IN2014DN10084A (es)
LT (4)	LT3348553T (es)
LU (1)	LUC00236I2 (es)
ME (2)	ME03815B (es)
MX (1)	MX356754B (es)
MY (1)	MY187500A (es)
NI (1)	NI201400142A (es)
NL (1)	NL301144I2 (es)
NO (1)	NO2021046I1 (es)
NZ (2)	NZ702203A (es)
PE (3)	PE20200795A1 (es)
PH (2)	PH12014502714B1 (es)
PL (3)	PL3533792T3 (es)
PT (3)	PT3348553T (es)
RS (3)	RS60617B1 (es)
SG (3)	SG10201610249TA (es)
SI (3)	SI2858985T1 (es)
SM (3)	SMT202000496T1 (es)
TR (1)	TR201808939T4 (es)
TW (1)	TWI532732B (es)
UA (2)	UA123142C2 (es)
WO (1)	WO2013184681A1 (es)
ZA (1)	ZA201500076B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008119015A2 (en)	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
AP2014007657A0 (en)	2011-12-16	2014-05-31	Olema Pharmaceuticals Inc	Novel benzopyran compounds, compositions and uses thereof
PL3533792T3 (pl)	2012-06-07	2021-11-29	Aragon Pharmaceuticals, Inc.	Postacie krystaliczne modulatora receptora androgenowego
CN105358535B (zh)	2012-09-11	2019-01-04	麦迪威森前列腺医疗有限责任公司	恩杂鲁胺制剂
AU2013323861C1 (en)	2012-09-26	2024-05-02	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) *	2014-08-26	2017-09-07	アスターバイオテックリミテッドライアビリティカンパニー	プロテインキナーゼ阻害剤
KR102348325B1 (ko)	2014-12-05	2022-01-06	아라곤 파마슈티컬스, 인코포레이티드	항암 조성물
TWI709403B (zh)	2014-12-05	2020-11-11	美商艾瑞岡醫藥公司	抗癌症組成物（二）
PL3226841T3 (pl)	2014-12-05	2025-03-03	Aragon Pharmaceuticals, Inc.	Kompozycje przeciwnowotworowe
EP3235345B1 (en)	2014-12-19	2024-03-06	Lutron Technology Company LLC	Multi-channel lighting fixture having multiple light-emitting diode drivers
UA124154C2 (uk)	2016-06-03	2021-07-28	Арагон Фармасьютікалз, Інк.	Протиракові композиції
RU2019121700A (ru)	2016-12-13	2021-01-15	Ватсон Лэборетериз Инк.	Твердые формы апалутамида
CN111479560A (zh)	2017-10-16	2020-07-31	阿拉贡药品公司	用于治疗非转移性去势难治性前列腺癌的抗雄激素
WO2019135254A1 (en)	2018-01-02	2019-07-11	Mylan Laboratories Limited	Apalutamide polymorphs and their preparation thereof
KR20210023987A (ko) *	2018-06-20	2021-03-04	크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디.	Arn-509의 결정형, 그 제조방법 및 그 용도
WO2020049598A2 (en)	2018-09-08	2020-03-12	Cipla Limited	Apalutamide polymorphs
IT201900003839A1 (it)	2019-03-15	2020-09-15	Olon Spa	Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) *	2019-05-21	2020-11-26	Laurus Labs Limited	Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it)	2019-07-01	2021-01-01	Dipharma Francis Srl	Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) *	2019-08-22	2022-06-29	Dr. Reddy's Laboratories Ltd.	Process for the preparation of apalutamide
IT201900015974A1 (it)	2019-09-10	2021-03-10	Olon Spa	Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) *	2019-09-20	2019-12-20	武汉大学	一种阿帕鲁胺化合物及其药物制剂
US20230312507A1 (en)	2020-09-04	2023-10-05	Synthon B.V.	Improved process for preparation of apalutamide
CN112679468A (zh) *	2021-01-05	2021-04-20	四川科伦药物研究院有限公司	阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) *	2022-01-25	2023-08-03	成都苑东生物制药股份有限公司	一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) *	2022-10-17	2024-06-11	上海博悦生物科技有限公司	一种阿帕他胺的合成方法
CN116332907A (zh) *	2023-03-16	2023-06-27	奥锐特药业股份有限公司	一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) *	2024-01-18	2025-07-24	Nanoform Finland Oyj	Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CN101032483B (zh)	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
SI2656841T1 (sl)	2006-03-27	2016-11-30	The Regents Of The University Of California	Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji
EP3020706A1 (en) *	2006-03-29	2016-05-18	The Regents Of The University Of California	Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
WO2008119015A2 (en) *	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
LT3124481T (lt) *	2010-02-16	2018-06-11	Aragon Pharmaceuticals, Inc.	Androgeno receptorių moduliatoriai ir jų panaudojimas
PL3533792T3 (pl) *	2012-06-07	2021-11-29	Aragon Pharmaceuticals, Inc.	Postacie krystaliczne modulatora receptora androgenowego
KR20210023987A (ko)	2018-06-20	2021-03-04	크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디.	Arn-509의 결정형, 그 제조방법 및 그 용도

2013
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 SM SM20200496T patent/SMT202000496T1/it unknown
- 2013-06-04 SM SM20210355T patent/SMT202100355T1/it unknown
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active Active
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 PE PE2020000234A patent/PE20200795A1/es unknown
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 SM SM20180311T patent/SMT201800311T1/it unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 IL IL267608A patent/IL267608B2/en unknown
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 IL IL320522A patent/IL320522A/en unknown
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en not_active Ceased
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en not_active Revoked
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active Active
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 HK HK15111086.5A patent/HK1210175A1/xx unknown
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389.2A patent/HK1226066A1/zh unknown
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
2021
- 2021-01-26 US US17/158,806 patent/US12018008B2/en active Active
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-02 LU LU00236C patent/LUC00236I2/fr unknown
- 2021-11-03 LT LTPA2021525C patent/LTC3533792I2/lt unknown
- 2021-11-03 NL NL301144C patent/NL301144I2/nl unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
- 2021-11-04 CY CY2021032C patent/CY2021032I2/el unknown
2024
- 2024-05-13 US US18/662,345 patent/US20250092011A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US10526310B2 (en)	2020-01-07
TWI532732B (zh)	2016-05-11
PT2858985T (pt)	2018-07-10
FR21C1050I2 (fr)	2024-05-24
SG10201610249TA (en)	2017-02-27
AU2017200298B2 (en)	2017-09-28
US20210163441A1 (en)	2021-06-03
US10556882B2 (en)	2020-02-11
AU2017279807B2 (en)	2018-11-08
PT3348553T (pt)	2020-09-28
EP2858985A1 (en)	2015-04-15
CL2014003331A1 (es)	2016-03-04
NZ702203A (en)	2016-09-30
IL259738B (en)	2021-06-30
CY2021032I2 (el)	2022-03-24
SI3348553T1 (sl)	2020-11-30
PH12016501470B1 (en)	2021-12-10
CN105693692A (zh)	2016-06-22
HUE038082T2 (hu)	2018-09-28
EP3348553B1 (en)	2020-07-08
US9481663B2 (en)	2016-11-01
NL301144I2 (nl)	2025-03-20
LT3533792T (lt)	2021-07-26
US20150133481A1 (en)	2015-05-14
ME03081B (me)	2019-01-20
LTC3533792I2 (es)	2024-07-10
US10308630B2 (en)	2019-06-04
HRP20201387T1 (hr)	2020-11-27
SG11201408140QA (en)	2015-01-29
LTPA2021525I1 (es)	2021-11-25
IL267608B2 (en)	2025-10-01
US10766875B2 (en)	2020-09-08
US12018008B2 (en)	2024-06-25
AU2017279807A1 (en)	2018-01-25
IL259738A (en)	2018-07-31
KR20150021993A (ko)	2015-03-03
CY1124831T1 (el)	2022-03-24
US20170001977A1 (en)	2017-01-05
PL3533792T3 (pl)	2021-11-29
HRP20210909T1 (hr)	2021-09-03
PE20200795A1 (es)	2020-08-10
ECSP14030098A (es)	2016-01-29
EP2858985B1 (en)	2018-04-18
EA028791B1 (ru)	2017-12-29
CA3114726A1 (en)	2013-12-12
JP6345821B2 (ja)	2018-06-20
JP2017178923A (ja)	2017-10-05
CY1123427T1 (el)	2021-12-31
US20180258067A1 (en)	2018-09-13
PH12016501470A1 (en)	2017-07-10
CA3008345A1 (en)	2013-12-12
EA201992010A1 (ru)	2020-01-24
RS61988B1 (sr)	2021-07-30
CO7240407A2 (es)	2015-04-17
JP2018141009A (ja)	2018-09-13
CN104619692A (zh)	2015-05-13
MX2014015005A (es)	2015-09-04
PH12014502714A1 (en)	2015-02-02
US20200354335A1 (en)	2020-11-12
ES2670683T3 (es)	2018-05-31
HUE050357T2 (hu)	2020-11-30
KR102195916B1 (ko)	2020-12-30
DK2858985T3 (en)	2018-05-28
US20190330182A1 (en)	2019-10-31
ZA201500076B (en)	2016-10-26
RS57370B1 (sr)	2018-08-31
ES2875932T3 (es)	2021-11-11
EA201791592A1 (ru)	2018-01-31
GT201400283A (es)	2017-07-03
ES2809738T3 (es)	2021-03-05
ME03815B (me)	2021-04-20
BR112014030678A2 (pt)	2017-06-27
HRP20180902T1 (hr)	2018-08-24
IL236055A0 (en)	2015-02-01
CY2021032I1 (es)	2022-03-24
SMT202100355T1 (it)	2021-07-12
MX356754B (es)	2018-06-11
HK1210175A1 (en)	2016-04-15
IL320522A (en)	2025-06-01
DK3533792T3 (da)	2021-06-28
CA3008345C (en)	2019-10-22
TW201402561A (zh)	2014-01-16
EP3348553A1 (en)	2018-07-18
IL267608A (en)	2019-08-29
RS60617B1 (sr)	2020-09-30
AU2013271751B2 (en)	2017-02-23
EA033956B1 (ru)	2019-12-13
CA2875767C (en)	2018-08-14
US20190241539A1 (en)	2019-08-08
AU2017200298A1 (en)	2017-02-02
PL3348553T3 (pl)	2021-02-08
EP2858985A4 (en)	2016-05-25
JP6182209B2 (ja)	2017-08-16
US20250092011A1 (en)	2025-03-20
DK3348553T3 (da)	2020-07-27
HUS2100047I1 (hu)	2021-11-29
UA115665C2 (uk)	2017-12-11
EP3922629A1 (en)	2021-12-15
IL275413A (en)	2020-07-30
FR21C1050I1 (fr)	2021-12-10
CA2875767A1 (en)	2013-12-12
PE20200725A1 (es)	2020-07-21
EP3533792A1 (en)	2019-09-04
KR102062024B1 (ko)	2020-01-03
SMT202000496T1 (it)	2020-11-10
KR20190132543A (ko)	2019-11-27
SI3533792T1 (sl)	2021-11-30
NI201400142A (es)	2016-12-02
US10934271B2 (en)	2021-03-02
HK1226066A1 (zh)	2017-09-22
CY1120393T1 (el)	2019-07-10
JP2015518890A (ja)	2015-07-06
EA201492272A1 (ru)	2015-05-29
SI2858985T1 (sl)	2018-12-31
PH12014502714B1 (en)	2015-02-02
IN2014DN10084A (es)	2015-08-21
PT3533792T (pt)	2021-06-07
HUE054595T2 (hu)	2021-09-28
CR20140549A (es)	2015-04-06
PE20150631A1 (es)	2015-05-11
SG10201610248SA (en)	2017-02-27
TR201808939T4 (tr)	2018-07-23
CA3055660A1 (en)	2013-12-12
NZ717683A (en)	2018-04-27
IL267608B1 (en)	2025-06-01
PL2858985T3 (pl)	2018-09-28
MY187500A (en)	2021-09-24
AU2013271751A1 (en)	2014-12-18
WO2013184681A1 (en)	2013-12-12
LT3348553T (lt)	2020-09-25
EP3533792B1 (en)	2021-05-05
UA123142C2 (uk)	2021-02-24
CN113135892A (zh)	2021-07-20
US20200115361A1 (en)	2020-04-16
SMT201800311T1 (it)	2018-07-17
LUC00236I2 (es)	2025-02-03
LT2858985T (lt)	2018-09-25
NO2021046I1 (no)	2021-11-02
US9994545B2 (en)	2018-06-12

Publication	Publication Date	Title
CR20190331A (es)	2019-11-12	UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
CL2017001984A1 (es)	2018-03-23	Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
GT201300215A (es)	2015-02-09	Inhibidores de glucosilceramida sintasa
CL2013002650A1 (es)	2013-12-06	Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
CU20150163A7 (es)	2016-05-30	DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
UY32809A (es)	2011-02-28	Compuestos y composiciones como inhibidores de cinasa s y k
NZ702663A (en)	2017-03-31	Nuclear transport modulators and uses thereof
MX2018001324A (es)	2018-04-30	Forma cristalina de base libre de lorlatinib.
MX370900B (es)	2020-01-09	Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2015001610A1 (es)	2015-08-07	Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
CO6331308A2 (es)	2011-10-20	Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
ECSP16012582A (es)	2018-09-30	Compuestos heterocíclicos y métodos de uso
MX2016013245A (es)	2017-01-16	Regimen de dosificacion de liberacion inmediata de moduladores s1p.
MX2014012742A (es)	2015-04-08	Composicion para el tratamiento de transtornos metabólicos.
GT201300304A (es)	2015-01-16	1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX367926B (es)	2019-09-12	Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2009000876A1 (es)	2010-05-14	Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
UY35037A (es)	2014-05-30	Composición antiparasitaria de amplio espectro de nitazoxanida,probióticos y prebióticos
ECSP099644A (es)	2009-10-30	Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CL2015002906A1 (es)	2016-05-06	Suministro al sistema nervioso central de agentes terapéuticos (divisional de solicitud 3656-2012)
ECSP15001225A (es)	2017-03-31	Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos
UY35348A (es)	2014-08-29	Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen